For decades, the medical community has offered the same advice to the estimated 35 million Americans living with nail fungus: apply a topical cream, be consistent, and wait. For most, the result has been the same — months of treatment with little to no visible improvement. A growing body of research now suggests the problem was never the medicine itself.
A study published in the Journal of Fungi has identified a structural defense mechanism inside infected toenails that researchers believe may fundamentally change how dermatologists approach treatment. The finding has drawn particular attention because it offers what may be the first coherent explanation for one of the most common patient complaints in podiatric medicine: Why does nothing work?
The answer, according to researchers at the University of Wisconsin, lies in what happens during the first three days after fungal cells colonize the nail bed. The fungus doesn't simply grow. It constructs a biofilm — a structured, self-sealing colony encased in a protective biological matrix. And once that structure is in place, the rules of topical treatment change entirely.
Their data indicates that within 72 hours, the biofilm renders the fungal colony up to 50 times more resistant to conventional antifungal agents applied to the nail surface.
“What's particularly significant is how fast this happens. Within three days the fungus has essentially armored itself. After that, topical treatments — creams, oils, even prescription drops — they dry up on the surface within minutes. They never reach the fungus.”
The implications are significant. If the biofilm forms within the first 72 hours — and virtually all diagnosed infections are well past that window — then every cream, oil, and over-the-counter treatment applied to the surface of the nail is functionally unable to reach the actual fungus colony underneath.
The medicine isn't too weak. It simply can't get there.
Why Decades of Treatment Have Failed
The finding offers a potential explanation for one of dermatology's most persistent frustrations. Nail fungus — clinically known as onychomycosis — affects roughly 14% of the general population. It is one of the most commonly reported conditions in podiatric medicine, yet its treatment success rates remain among the lowest.
Topical antifungal creams, the most commonly recommended first-line treatment, have shown cure rates as low as 5–8% in clinical settings. Even prescription-grade topical solutions, which can cost $300–$800 per course, show efficacy rates well below 30%.
Dr. Mitchell and her team believe the biofilm is the missing variable.
What Is a Fungal Biofilm?
A biofilm is not a single organism. It is an organized community of fungal cells that adhere to a surface — in this case, the underside of the nail plate — and encase themselves in a self-produced matrix of proteins and polysaccharides. This matrix acts as a physical and chemical shield, dramatically reducing the ability of antifungal agents to penetrate and reach the living cells within.
Once established, biofilms are extremely difficult to disrupt through surface application alone. Researchers compare them to a fortress: the walls don't just protect — they actively repel outside agents.
"The treatment paradigm for nail fungus has been based on the assumption that if you apply a strong enough antifungal to the nail, it will eventually reach the infection," Dr. Mitchell explains. "But what our research shows is that the nail plate itself — combined with the biofilm — creates a double barrier. The medicine dries up on the surface within minutes. It physically cannot make sustained contact with the fungus."
This may explain why millions of people who have diligently applied creams and oils for months — sometimes years — have seen no lasting improvement. The problem was never the medicine. The problem was delivery.
The Oral Medication Dilemma
For patients who have exhausted topical options, oral antifungal medications such as terbinafine have long been positioned as the more effective alternative. Taken in pill form, these medications bypass the nail plate entirely, reaching the infection through the bloodstream.
However, oral antifungals carry well-documented risks. Terbinafine requires liver function monitoring through regular blood tests. A subset of patients experience hepatotoxicity — liver damage — that ranges from elevated enzymes to, in rare cases, liver failure requiring hospitalization.
For patients with pre-existing liver conditions, those taking other medications processed by the liver, pregnant or breastfeeding women, and elderly patients, oral antifungals are often contraindicated entirely. These patients are left in a treatment gap: topical treatments can't reach the fungus, and the one treatment that can is too risky to use.
A Delivery Problem, Not an Ingredient Problem
If the biofilm is the obstacle, and surface-applied treatments cannot maintain contact long enough to penetrate it, then the question shifts from pharmacology to engineering: how do you keep an active compound sealed against the nail long enough for it to actually get through?
This is the question behind a growing field of research into occlusive transungual delivery — a term for treatment systems designed to maintain prolonged, sealed contact with the nail surface. The principle is straightforward but represents a departure from how most topical treatments are formulated.
Dr. Mitchell explains the physics: "A cream or oil applied to the nail surface begins evaporating almost immediately. Within two to three minutes, the active ingredient has lost its contact with the nail. That is not enough time to soften keratin, let alone penetrate through to the biofilm. The antifungal compound needs hours, not minutes."
